Page last updated: 2024-12-08

1,1-hydroxyoctanodiphosphonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You are likely referring to **1,1-hydroxyoctanedisphosphonate (1,1-HDP)**, not hydroxyoctanodiphosphonate.

**1,1-HDP** is a synthetic compound that acts as a potent and selective inhibitor of **hydroxyapatite formation**. Hydroxyapatite is the primary mineral component of bones and teeth.

Here's why it is important in research:

* **Bone and Tooth Research:** 1,1-HDP's ability to inhibit hydroxyapatite formation makes it a valuable tool for studying bone and tooth development, regeneration, and disease. Researchers use it to:
* **Investigate the mechanisms of bone and tooth mineralization:** By blocking hydroxyapatite formation, they can observe how bone cells and other factors influence this process.
* **Develop new treatments for bone disorders:** 1,1-HDP can be used to study the effects of potential drugs and therapies on bone formation.
* **Develop new biomaterials for bone regeneration:** Its ability to inhibit hydroxyapatite formation can be harnessed to create biocompatible materials that promote bone growth.

* **Dental Research:** 1,1-HDP is also used in dental research to:
* **Study the formation of dental calculus (tartar):** 1,1-HDP inhibits the mineralization of dental plaque, which is a crucial step in tartar formation.
* **Investigate new approaches to prevent tooth decay:** By understanding how 1,1-HDP affects tooth enamel formation, researchers can explore new ways to strengthen teeth and reduce the risk of cavities.

* **Other Applications:** 1,1-HDP has potential applications beyond bone and tooth research. For example, it is being explored for its ability to:
* **Inhibit the formation of kidney stones:** These stones are often composed of calcium oxalate, which is structurally similar to hydroxyapatite.
* **Control the growth of calcium phosphate biominerals in various industrial settings:** 1,1-HDP could be used to prevent the formation of unwanted calcium phosphate deposits in pipelines, boilers, and other industrial equipment.

In summary, 1,1-HDP is a powerful research tool with applications in a wide range of fields. Its ability to inhibit hydroxyapatite formation provides valuable insights into biological processes and opens up new possibilities for the development of innovative treatments and technologies.

Cross-References

ID SourceID
PubMed CID405400
CHEMBL ID298547
SCHEMBL ID4098579
MeSH IDM0231282

Synonyms (15)

Synonym
53019-19-5
phosphonic acid, (1-hydroxyoctylidene)bis-
(1-hydroxy-1-phosphono-octyl)phosphonic acid
(1-hydroxyoctylidene)bisphosphonic acid
1,1-hydroxyoctanodiphosphonate
(1-hydroxy-1-phosphonooctyl)phosphonic acid
CHEMBL298547 ,
(1-hydroxy-1-phosphono-octyl)-phosphonic acid
bdbm50097886
1-hydroxyoctane-1,1-diyldiphosphonic acid
nsc 722626
(1-hydroxyoctane-1,1-diyl)diphosphonic acid
SCHEMBL4098579
DTXSID90201064
(1-hydroxyoctane-1,1-diyl)diphosphonicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Geranylgeranyl pyrophosphate synthaseHomo sapiens (human)IC50 (µMol)4.30000.00401.02764.5000AID74507
Farnesyl pyrophosphate synthaseHomo sapiens (human)IC50 (µMol)13.22070.00020.71099.3600AID72667; AID72669; AID72670; AID72672
Farnesyl pyrophosphate synthaseHomo sapiens (human)Ki1.44000.00010.21651.9000AID72668; AID72673
Farnesyl pyrophosphate synthase Leishmania donovaniIC50 (µMol)19.94000.11000.15600.1700AID72651
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
isoprenoid metabolic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranylgeranyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
isoprenoid biosynthetic processGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cholesterol biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
dimethylallyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
farnesyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
protein bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
identical protein bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
prenyltransferase activityGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
RNA bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
protein bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
dimethylallyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
cytosolGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
Z discGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
perinuclear region of cytoplasmGeranylgeranyl pyrophosphate synthaseHomo sapiens (human)
nucleoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytosolFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID213660In vitro antiparasitic activity against Trypanosoma cruzi (amastigotes)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
AID213817Maximum inhibitory activity against Trypanosoma cruzi (epimastigotes)2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
AID72673Binding affinity towards Trypanosoma cruzi farnesyl pyrophosphate synthase (TcFPPS)2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
AID213789Inhibitory concentration against Trypanosoma cruzi (amastigotes)2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID235248Therapeutic index was expressed as ratio of LD50 for KB cell line to IC50 against Plasmodium falciparum2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID72672Inhibition of Trypanosoma cruzi farnesyl pyrophosphate synthase2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
AID96034Toxicity evaluated against human nasopharyngeal carcinoma KB cell line2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID213661In vitro antiparasitic activity against Trypanosoma cruzi (epimastigotes)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
AID244679Therapeutic index (TI) value as ratio of lethal dose (LD50) to the inhibitory concentration (IC50)2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID158550In vitro growth inhibition against Plasmodium falciparum2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID67525In vitro growth inhibition against Entamoeba histolytica2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID249161Lethal dose required to inhibit the growth of human KB (nasopharyngeal carcinoma) cell line2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID1880632Lipophilicity, logD of compound at pH 1.3 by shake flask method based 31P-NMR analysis2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Studying Lipophilicity Trends of Phosphorus Compounds by
AID72669Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M)2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID72667Inhibitory activity against farnesyl Pyrophosphate Synthase was determined2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID235247Therapeutic index was expressed as ratio of LD50 for KB cell line to IC50 against Entamoeba histolytica2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID213791Inhibitory concentration against Trypanosoma cruzi (epimastigotes)2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
AID72668Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
AID74507Inhibitory activity against the human recombinant geranylgeranyl diphosphate synthase (GGPPSase).2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID72651Inhibitory activity against Leishmania major Farnesyl diphosphate synthase2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
AID248772In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
AID72670Inhibitory concentration against Trypanosoma brucei farnesyl pyrophosphate synthase activity2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Bisphosphonates derived from fatty acids are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
AID213814In vitro inhibition of antiparasitic activity against Trypanosoma cruzi at 70 uM (amastigotes)2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Bisphosphonates derived from fatty acids are potent growth inhibitors of Trypanosoma cruzi.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (75.00)29.6817
2010's1 (12.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]